Filing summary
Entity and period: The supplied filing is Graphite Bio, Inc. (Nasdaq: GRPH), not LENZ Therapeutics, Inc. It is the Form 10-K for the fiscal year ended December 31, 2021; it does not provide standalone fourth-quarter financial results.
Business context
Graphite Bio was a clinical-stage gene-editing company developing targeted gene integration therapies. Its lead candidate, GPH101, was in a Phase 1/2 trial for sickle cell disease (SCD); the first patient was enrolled in November 2021. Other programs were preclinical or earlier-stage. The company had no approved products and had generated no product revenue.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $37.9 million | $9.1 million |
| General and administrative expense | $22.5 million | $4.4 million |
| Total operating expenses / operating loss | $60.4 million | $13.5 million |
| Net loss | $70.8 million | $68.4 million |
| Net loss per share, basic and diluted | $2.45 | $29.93 |
| Cash used in operating activities | $52.9 million | $8.7 million |
| Cash used in investing activities | $5.7 million | $1.5 million |
| Cash provided by financing activities | $417.5 million | $30.1 million |
At December 31, 2021, cash and cash equivalents were $377.0 million and restricted cash was $1.7 million, for $378.7 million in total. Total assets were $402.0 million; total liabilities were $17.9 million. The balance sheet reported no outstanding convertible notes or other borrowings. Operating lease liabilities totaled $11.3 million. A separate 10-year lease for future facilities had $81.0 million of minimum payments; it had not commenced and was not recorded as a lease liability at year-end.
There are no meaningful product margins to assess because the company had no product sales. The filing reports an accumulated deficit of $141.4 million. Management estimated that year-end cash would fund operations and capital expenditures into the fourth quarter of 2024 under its then-current plan.
Changes versus the prior year
- R&D expense rose $28.8 million, mainly from clinical and manufacturing activity, personnel, and facility-related costs.
- G&A expense increased $18.1 million, reflecting increased staffing and professional, insurance, and public-company costs.
- Net loss increased by $2.4 million despite much higher operating expenses. The 2020 loss included a $54.8 million charge from remeasurement of a preferred-stock tranche liability, compared with $10.3 million in 2021.
- Operating cash use increased substantially. The 2021 IPO generated approximately $251.3 million in net proceeds, and preferred-stock financing contributed additional funding.
Outlook, risks, and unusual items
- Management planned to dose the first GPH101 patient in the second half of 2022 and anticipated initial proof-of-concept data in 2023. It targeted an IND filing for GPH102 by mid-2024, subject to health-authority feedback.
- COVID-19, including the Omicron surge, affected trial-site staffing and enrollment; infection of a prospective participant delayed first-patient treatment. Further trial, manufacturing, or regulatory delays remained possible.
- The company expected continued losses and substantial funding needs. Its runway estimate depended on the operating plan; spending changes or delays could bring forward the need for financing.
- Key risks included early-stage clinical and gene-editing safety uncertainty, patient enrollment, reliance on third-party manufacturers and other vendors, competition, regulatory approval, intellectual-property disputes, and access to future capital.
- The company had no material legal proceedings reported. Its financial statements received an unqualified audit opinion. As an emerging growth company, it did not include an auditor attestation on internal control over financial reporting; management reported disclosure controls were effective.
- Unusual financing-related accounting affected comparability: preferred-stock tranche-liability fair-value changes materially affected reported losses in both years. The IPO and conversion of preferred stock to common stock also significantly changed the capital structure.
Important facts for investors to verify
- Confirm the intended issuer: this filing is Graphite Bio, not LENZ Therapeutics.
- Check subsequent filings for actual GPH101 dosing, trial progress, safety findings, and data timing versus the stated plans.
- Reassess cash runway using later cash balances, operating cash use, financing, and changes to development plans.
- Review third-party manufacturing capacity, facility and lease commitments, and any additional financing or dilution.
- Track the status and scope of licensed intellectual property, including Stanford and IDT obligations and any relevant patent challenges.